Costly Assay Applications Prompt OIVD To Reconsider Bundling Policy
This article was originally published in The Gray Sheet
FDA's Office of In Vitro Diagnostic Device Evaluation & Safety is showing a willingness to depart from bundling precedent in cases where user fee costs are overly burdensome to manufacturers and a premarket review package acceptable to OIVD divisions can be assembled
You may also be interested in...
Modular premarket applications will be exempt from device user fees if FDA received the initial module of the PMA prior to Oct. 1, 2002
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.